Comparisons between multicenter studies of bendamustine treatment for relapsed or refractory myeloma.

Table 3Comparisons between multicenter studies of bendamustine treatment for relapsed or refractory myeloma.

^a)This study just described the percentage of patients exposed to immunomodulatory drugs. ^b)The ORR of the study included the response rates of different regimens. ^c)The hematologic toxicity was based on grade 3/4 anemia. ^d)The hematologic toxicity was based on grade 3/4 neutropenia.

Abbreviations: G, grade; OS, overall survival; PR, partial response; SCT, stem cell transplantation.

Blood Res 2016;51:193~199 https://doi.org/10.5045/br.2016.51.3.193